文献速递临床试验与 GCP流行病学与生物统计

维利西呱对射血分数保留心衰患者生活质量的影响:VITALITY-HFpEF随机临床试验

Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

VITALITY-HFpEF为2b期随机双盲安慰剂对照多中心试验,纳入789例慢性HFpEF且近期失代偿患者,比较维利西呱15 mg/d、10 mg/d与安慰剂。治疗24周后,两剂量组KCCQ躯体受限评分较安慰剂的差异均无统计学意义。

要点

  • 维利西呱15 mg/d与10 mg/d均未显著改善24周KCCQ躯体受限评分
  • 6分钟步行距离在各组间差异亦无统计学意义
  • 症状性低血压在15 mg/d组为6.4%,晕厥发生率低

核心结论

  • 在HFpEF且近期失代偿患者中,维利西呱15 mg/d或10 mg/d治疗24周未改善KCCQ躯体受限评分。

研究设计与样本

  • 2b期随机、双盲、安慰剂对照、多中心试验,789例慢性HFpEF患者按1:1:1随机分组。
  • 入组LVEF≥45%、NYHA II-III级、6个月内有近期失代偿且利钠肽升高,来自21个国家167个中心。

主要发现

  • 15 mg/d组与安慰剂组KCCQ PLS最小二乘均值差为-1.5(95%CI,-5.5至2.5;P=.47)。
  • 10 mg/d组与安慰剂组KCCQ PLS最小二乘均值差为-0.5(95%CI,-4.6至3.5;P=.80)。
  • 6分钟步行距离15 mg/d组与安慰剂组差-5.5 m(95%CI,-19.7至8.8;P=.45)。
  • 6分钟步行距离10 mg/d组与安慰剂组差-1.8 m(95%CI,-16.2至12.6;P=.81)。
  • 症状性低血压发生率15 mg/d组6.4%、10 mg/d组4.2%、安慰剂组3.4%。

关键数值与推荐

  • KCCQ PLS范围0-100,分值越高功能越好;主要终点为治疗24周时评分变化。
  • 基线至24周KCCQ PLS均值:15 mg/d组60.0至68.3,10 mg/d组57.3至69.0,安慰剂组59.0至67.1。

临床怎么用

  • 对于HFpEF且近期失代偿患者,维利西呱在改善躯体受限和生活质量方面未显示优于安慰剂。
  • 用药决策需结合症状性低血压等耐受性事件个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with heart failure and preserved ejection fraction (HFpEF) are at high risk of mortality, hospitalizations, and reduced functional capacity and quality of life. OBJECTIVE: To assess the efficacy of the oral soluble guanylate cyclase stimulator vericiguat on the physical limitation score (PLS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ). DESIGN, SETTING, AND PARTICIPANTS: Phase 2b randomized, double-blind, placebo-controlled, multicenter trial of 789 patients with chronic HFpEF and left ventricular ejection fraction 45% or higher with New York Heart Association class II-III symptoms, within 6 months of a recent decompensation (HF hospitalization or intravenous diuretics for HF without hospitalization), and with elevated natriuretic peptides, enrolled at 167 sites in 21 countries from June 15, 2018, through March 27, 2019; follow-up was completed on November 4, 2019. INTERVENTIONS: Patients were randomized to receive vericiguat, up-titrated to 15-mg (n = 264) or 10-mg (n = 263) daily oral dosages, compared with placebo (n = 262) and randomized 1:1:1. MAIN OUTCOMES AND MEASURES: The primary outcome was change in the KCCQ PLS (range, 0-100; higher values indicate better functioning) after 24 weeks of treatment. The secondary outcome was 6-minute walking distance from baseline to 24 weeks. RESULTS: Among 789 randomized patients, the mean age was 72.7 (SD, 9.4) years; 385 (49%) were female; mean EF was 56%; and median N-terminal pro-brain natriuretic peptide level was 1403 pg/mL; 761 (96.5%) completed the trial. The baseline and 24-week KCCQ PLS means for the 15-mg/d vericiguat, 10-mg/d vericiguat, and placebo groups were 60.0 and 68.3, 57.3 and 69.0, and 59.0 and 67.1, respectively, and the least-squares mean changes were 5.5, 6.4, and 6.9, respectively. The least-squares mean difference in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.5 to 2.5; P = .47) and between the 10-mg/d vericiguat and placebo groups was -0.5 (95% CI, -4.6 to 3.5; P = .80). The baseline and 24-week 6-minute walking distance mean scores in the 15-mg/d vericiguat, 10-mg/d vericiguat, and placebo groups were 295.0 m and 311.8m , 292.1 m and 318.3 m, and 295.8 m and 311.4 m, and the least-squares mean changes were 5.0 m, 8.7 m, and 10.5 m, respectively. The least-squares mean difference between the 15-mg/d vericiguat and placebo groups was -5.5 m (95% CI, -19.7 m to 8.8 m; P = .45) and between the 10-mg/d vericiguat and placebo groups was -1.8 m (95% CI, -16.2 m to 12.6 m; P = .81), respectively. The proportions of patients who experienced symptomatic hypotension were 6.4% in the 15-mg/d vericiguat group, 4.2% in the 10-mg/d vericiguat group, and 3.4% in the placebo group; those with syncope were 1.5%, 0.8%, and 0.4%, respectively. CONCLUSIONS AND RELEVANCE: Among patients with HFpEF and recent decompensation, 24-week treatment with vericiguat at either 15-mg/d or 10-mg/d dosages compared with placebo did not improve the physical limitation score of the KCCQ. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03547583.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA. 2020. PMID: 33079152. doi:10.1001/jama.2020.15922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。